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A cute liver failure (ALF) is a rare disease associated with high short-term morbidity and mortality. 1 In the United States, hepatitis B virus (HBV)-associated ALF represents about 7% of all ALF events. 2 It may develop following acute or reactivation of chronic HBV infection. Among causes of reactivation, the use of immunosuppressive agents, mostly to treat autoimmune diseases or cancer, has been recognized as an increasingly important issue. 3, 4 In a recent American Gastroenterological Association technical review, patients who were hepatitis B surface antigen (HBsAg)/anti-hepatitis B core antibody (HBc) positive had a reactivation rate of up to 30% if receiving anthracycline-based chemotherapy, whereas those who received B-cell depleting agents (rituximab) achieved reactivation rates as high as 60%. 5 These patients are potentially at risk for ALF, and furthermore, given their own comorbidities, they may have contraindications that could preclude liver transplantation (LT). Fortunately, the risk of reactivation of chronic HBV infection in this context may be mitigated with appropriate antiviral prophylaxis. 6, 7 Studies have suggested that HBV-associated ALF caused by immunosuppression treatment may have a specific pathophysiology, because it has been noted that these patients frequently display specific HBsAg mutations that may enhance the virus' capability of evading the immune system response. 8, 9 Other mechanisms that have been postulated include loss of immune control of viral replication via inhibition of gamma interferons, upregulated cytotoxic T-cell-mediated hepatocyte necrosis, and B-cell depletion. 7, 10, 11 The outcomes of patients with HBV-associated ALF caused by immunosuppression have been poorly studied. 9 Taking into account the increasing burden of all immunosuppressive treatments for health care systems worldwide, this study aimed to evaluate the proportion of patients with HBV-associated ALF in a large North American cohort caused by immunosuppression (US ALF Study Group [US ALFSG]), to determine if there is an association between immunosuppression/chemotherapy (exposure) and decreased transplant-free survival (TFS) (and overall) survival in 156 patients with HBVassociated ALF from the US-ALFSG registry, and to determine if the presence of immunosuppression is associated with worse TFS to HBV-associated ALF control subjects after adjusting for other significant covariates (multivariable logistic regression).
Methods

Design, Setting, Participants
We performed a retrospective cohort study of all adjudicated patients with HBV-associated ALF within the US ALFSG prospective registry between January 1998 and April 2015. Patients not fulfilling criteria for ALF (see operational definitions) or with unknown primary outcome data were excluded. All participating sites were tertiary academic liver transplant referral centers. 12 This study's protocol has been approved by the institutional review boards or health research ethics boards of all enrolling US ALFSG sites (see acknowledgements). Informed consent was obtained from next of kin for all patients because subjects were unable to provide consent (hepatic encephalopathy [HE] ). All research procedures were conducted according to the principles of the Declaration of Helsinki. 13 
Data Collection
Patients were enrolled prospectively into a database (coordinating center at University of Texas Southwestern Medical Center) where demographic, clinical, and outcome data on patients with ALF were recorded. Baseline clinical data on patients with HBV-associated ALF included serologic testing, hepatic panel biochemistry, HE grade (West Haven criteria) on admission, Model for End-Stage Liver Disease (MELD) score, King's College criteria fulfillment (admission), serologic profile of HBV and hepatitis D virus (admission and on history if available), history of human immunodeficiency virus, and previous use of immunosuppressive treatments. Clinical data, medical therapies, and complications in the first 7 days post study enrollment were recorded. Data were retrieved on outcomes at 21 days post study enrollment TFS, LT, and overall survival.
Operational Definitions: Inclusion Criteria ALF was defined according to the following criteria: (1) HE of any degree, (2) evidence of coagulopathy with international normalized ratio !1.5, (3) acute illness onset <26 weeks, and (4) no evidence of cirrhosis.
14 Patients were considered to have HBV-associated ALF when serologic testing for HBsAg and/or IgM anti-HBc was positive.
2 HBV-associated ALF caused by immunosuppression was defined in the setting of clinical or serologic evidence of HBV-associated ALF (reactivation) and a history of immunosuppressive treatment. 9 The MELD score is described elsewhere and has been applied previously to predict outcomes of patients with ALF. [15] [16] [17] The King's College criteria have been widely used for prognostication in ALF and to determine which patients will most likely benefit from emergent LT. 18 The nonacetaminopheninduced ALF criteria were used in this analysis. 19 
Outcomes
The exposure of interest in the study was exposure to chemotherapy or immunosuppression. The primary outcome was defined as TFS at 21 days post study enrollment because this was thought to better depict the clinical course of HBV-associated ALF after immunosuppression, given that it does not take into account the effect of LT. Secondary outcomes were LT rate and overall survival at 21 days post study enrollment.
Statistical Analyses
Categorical variables were presented as proportions, and comparisons were performed using the chi-square or Fisher exact test where appropriate (<5 cases). Continuous variables are presented as medians with interquartile ranges. Univariate comparisons were performed using the Kruskall-Wallis test. Statistical significance was defined as a P value < .05 for all comparisons. Multivariate analysis was performed with logistic regression. Covariates initially considered for modeling were chosen based on clinical relevance or a P < .10 on univariate comparisons. Collinearity was determined and avoided where appropriate. Final model performance was assessed by C statistic. All statistical analyses were done using SAS-STAT software, version 9.4 (SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics of Patients With Hepatitis B Virus-Acute Liver Failure
A total of 156 consecutive patients with HBVassociated ALF were identified in the US ALFSG registry for the period of time considered. There were 28 (17.9%) patients with HBV-associated ALF after immunosuppression and 128 (82.1%) were HBV-associated ALF control subjects. Of the 28 HBV-associated ALF after immunosuppression, HBV serologies, diagnoses (eg, malignancy), and immunosuppressant therapy (chemotherapy, corticosteroids) are listed in Table 1 . Within this subgroup, 15 patients received systemic corticosteroids as part of therapy, whereas 21 patients received chemotherapy. Twenty-two patients had solid or blood malignancy. Table 2 summarizes the baseline characteristics of all patients with HBV-associated ALF included stratified by group: HBV-associated ALF after immunosuppressive therapy versus control subjects. Immunosuppressed patients were significantly older (51.5 vs 41.0 years; P ¼ .0014), more often nonwhite and non-African American (50.0% vs 14.1%; P ¼ .0001), and had lower levels of platelets (118 vs 165 Â 10 9 /L; P < .0001) at admission in comparison with control subjects. Significantly more patients in the immunosuppressed group were previously identified (before the index hospital admission, available in 53 patients) as being HBsAg positive (64.3% vs 15.4%; P ¼ .0005). HBV serologic profile (see Table 2 ) for the index hospital admission was similar between groups (P > .17 for all comparisons) with the exception that significantly less HBV-associated ALF after immunosuppressive therapy patients were anti-HBc IgM positive (42.9% vs 85.6%; P < .0001).
Overall and TFS at 21 days following hospital admission for all patients with HBV-associated ALF in the overall cohort were 59.0% and 34.9%, respectively. On unadjusted analysis, there was some evidence that HBV-associated ALF after immunosuppressive therapy patients had lower overall 21-day survival than controls, although the association did not reach statistical significance (42.9% vs 62.5%, P ¼ .056). Similarly, there was a trend towards decreased unadjusted TFS at 21 days for immunosuppressed patients (21.4% vs 38.0%, P ¼ .097). The proportion of patients with HBV-associated ALF in the overall cohort who were listed for and who received LT during the 21-day study period were 46.4% and 33.3% (73.2% of the waitlisted patients), respectively. Rates of listing and receipt of LT were similar between groups ( Table 2 ; P > .4 for both comparisons). Of the 7 patients with HBV-associated ALF after immunosuppressive therapy who underwent LT, 3 patients were treated with chemotherapy for breast cancer, 2 for lymphoma, 1 patient had been treated with steroids for Guillain-Barré syndrome, and 1 with steroids for autoimmune hemolytic anemia (Table 1) .
Transplant-Free Survival at 21 Days Post Study Enrollment
Among the 156 patients with HBV-associated ALF initially included, 149 (95.5%) had available data on the primary outcome and were therefore considered for this analysis. Table 3 summarizes the baseline characteristics of these patients stratified by outcome at 21 days post study enrollment: TFS versus LT or death. Fifty-two (34.9%) patients spontaneously survived and 97 (65.1%) patients either underwent LT or died.
Patients with TFS had significantly lower international normalized ratio (2.2 vs 3.9) and MELD score (30.1 vs 40.7; P < .0001 for both) at admission than deceased/ transplanted HBV-ALF patients. TFS patients had fewer extrahepatic organ failures during the first 7 days post study enrollment, including grade III-IV HE (35.5% vs 78.9%; P < .0001), need for mechanical ventilation (21.6% vs 67.0%; P < .0001), vasopressor support (10.0% vs 32.0%; P ¼ .014), and renal-replacement therapy (2.0% vs 23.7%; P ¼ .0008). TFS patients fulfilled King's College criteria significantly less often (20.4% vs 46.2%; P ¼ .0026).
Multivariable Analysis: Independent Associations With 21-Day Transplant-Free Survival
After performing logistic regression analysis, the best final model for spontaneous survival at 21 days post study enrollment for all patients with HBV-associated ALF included 3 independent covariates (Table 4) . These were MELD (adjusted odds ratio per unit increment, 0.894), mechanical ventilation (adjusted odds 
Discussion
Key Results and Comparison With Literature
Using a large North American cohort of patients with HBV-associated ALF, we found that HBV-associated ALF after immunosuppressive therapy accounted for approximately one-fifth of overall HBV-ALF cases enrolled in the ALFSG registry. This analysis demonstrated that immunosuppressed patients significantly differed from the other patients with HBV-associated ALF in being older, more often nonwhite and non--African American, and more frequently had anemia and thrombocytopenia. Cytopenias may be related to these patients' underlying conditions (autoimmune diseases or cancer) and immunosuppressive treatments resulting in bone marrow toxicity. 20, 21 The HBV serologic profiles for the index hospital admission were similar between immunosuppressed patients and control subjects with the exception of anti-HBc IgM (higher in HBV-ALF control subjects). A recent study dedicated to evaluating differences in the HBV serologic profile between new-onset and reactivation-related HBV-associated ALF (all causes considered) demonstrated that high IgM anti-HBc titers and low HBV viral loads were characteristic of the new-onset (acute hepatitis B) subgroup, whereas the opposite was true for the reactivation-related subgroup. 9 In our study we did not find a significant difference in the HBV viral loads between patients with HBV-associated ALF caused by immunosuppression and control subjects and we did not have data on the IgM anti-HBc titers available. Nevertheless, although features of the HBV serologic profile may be a surrogate for the immune response to the virus and help to distinguish between new-onset and reactivation-related HBV-associated ALF, 9 it remains unclear whether they have a direct prognostic value.
In terms of outcomes, we showed that HBVassociated ALF overall frequently showed a poor shortterm prognosis, with only about one-third of patients spontaneously surviving at 21 days post study enrollment. Approximately one-third of all patients underwent LT during this period. It has been previously reported elsewhere that patients with HBV-associated ALF demonstrate worse outcomes than other ALF etiologies. 22, 23 Despite severity of organ dysfunction being similar, patients with HBV-associated ALF after immunosuppressive therapy had significantly worse (unadjusted) overall 21-day survival compared with control subjects. Given that the LT rate was similar between both groups (5 patients that received LT had known treated malignancy), we sought to determine which covariates most influenced TFS at 21 days post study enrollment for the entire cohort. In the univariate (unadjusted) analysis, we showed that the overall characteristics of the TFS group at 21 days post study enrollment differed from patients who underwent LT or died in demonstrating less severe organ failures (requirement for mechanical ventilation, vasopressors, or renal-replacement therapy), lower MELD scores, and less frequently demonstrating high grade (III-IV) HE. These findings are in keeping with previous reports stating that the prognosis of patients with ALF largely depends on the severity of organ failures that ensues. 24, 25 In the adjusted analysis, we found 3 factors that were independently associated with TFS at 21 days post hospital admission for patients with HBV-associated ALF: (1) MELD, (2) mechanical ventilation, and (3) receipt of immunosuppressive therapy. Of note, the prognostic ability of this model was deemed robust because C statistic was 0.866. The predictive value of MELD and mechanical ventilation quantified in the final model reinforces the argument that the severity of hepatic failure (international normalized ratio and bilirubin as part of MELD) and extrahepatic organ failures, namely renal (creatinine as part of MELD), respiratory, and neurologic (mechanical ventilation may have been needed for respiratory failure per se or because of coma) failures, are likely crucial for the short-term prognosis of patients with HBV-associated ALF. Two recent publications have emphasized the good prognostic ability of MELD in the setting of nonacetaminophen ALF. 16, 26 We demonstrated that receipt of immunosuppression was independently associated with lower spontaneous survival at 21 days in HBV-associated ALF. Potential explanations for this include a higher rate of prior/underlying liver disease correlating with chronic HBV infection. Although prehospital admission serology was known in only 53 patients, a higher percentage of immunosuppressed patients demonstrated a prior history of being HBsAg positive (9 of 14 [64.3%] vs 6 of 39 [15.4%]; P ¼ .0005). This could potentially suggest that immunosuppressed patients had less hepatic reserve despite similar hepatic synthetic parameters at presentation. These patients may have other reasons that predispose them to reactivation. In a recent study, 76% of patients with immune suppression-related reactivation of a chronic HBV infection carried HBsAg mutations localized in the immune-active HBsAg regions. 8 These HBVsAg mutations are thought to potentiate the virus' ability to evade the immune system, which might be deleterious by possibly contributing to the development of ALF. Finally, immunosuppressive therapy, particularly cytotoxic cancer chemotherapy, could potentially also interfere with hepatic regeneration.
According to our findings, HBV-associated ALF after immunosuppressive therapy has a poor prognosis emphasizing once more that clinicians need to initiate appropriate screening and preventive strategies before use of chemotherapy or immunotherapy, particularly in high-risk populations (prolonged steroids >4 weeks/ anthracycline/anti-CD 20 use). 5 Medical societies worldwide have produced guidelines on the theme and, despite some differences as to which patients should be prioritized for screening for HBV infection, they all agree that patients at high risk for immunosuppression-related reactivation of chronic HBV infection should be screened before starting immunosuppressive treatments. 24, 27 In a recent meta-analysis, Paul et al 6 demonstrated that prophylaxis significantly reduced rates of reactivation (odds ratio, 0.12) and HBV-related hepatitis (odds ratio, 0.18). Institutional protocols such as this may represent a decisive step forward in the prevention of immunosuppression HBV-ALF.
Limitations
This study has limitations that warrant consideration. First, because this was a cohort from North America, a region known to be nonendemic for HBV infection, our findings may be difficult to generalize to endemic areas of HBV infection. We also did not have complete data on prior HBsAg status (chronic carrier status) or data on anti-HBc IgM titers. Second, supportive therapeutic approaches to ALF and criteria for LT not only have been evolving over time but also may be center dependent, although a center effect could not be identified on multivariable analysis (P ¼ .6, data not shown). Third, although this was a large multicenter cohort where patients were prospectively enrolled into the registry, the retrospective nature of this study analysis implies that we can only comment on associations between covariates examined and not causation. Finally, rates of transplant in immunosuppressed patients were likely impacted by the fact that most patients had underlying malignancy, which could have precluded listing for LT. Nonetheless, this analysis was based on the largest Northern American cohort of patients with HBVassociated ALF. In being a rare but potentially devastating disease, findings determined in the analysis raise an important public health issue.
Conclusions
HBV-associated ALF caused by immunosuppression/ chemotherapy represents approximately one-fifth of all patients with HBV-associated ALF in the US ALFSG registry. Only one-fifth of immunosuppressed patients were alive at 21 days post hospital admission in the absence of LT. Independent factors associated with TFS for patients in HBV-associated ALF were MELD, mechanical ventilation, and use of immunosuppression/chemotherapy. Taking into account the poor prognosis of patients with HBV-associated ALF caused by immunosuppression and possible contraindications for LT, this represents a significant public health issue where preventive strategies need to be reinforced. 
